| Clinical and laboratory findings | TST positive () | TST negative () | value |
| Age, years, mean ± SD | | | 0.25 | Patients with risk factors for LTBI, (%) | 2 (33) | 7 (8) | 0.10 | SLE duration, median (IQR) | 90 (21–237) | 144 (60–225) | 0.72 | SLEDAI, mean ± SD | | | 0.64 | SLICC, median (IQR) | 0 (0-1) | 0 (0-1) | 0.78 | dsDNAn, UI/mL, median (IQR) | 29 (2.45–61.25) | 13.50 (4.77–42.75) | 0.71 | Prednisone > 7.5 mg/d, (%) | 0 (0) | 18 (32) | 0.68 | Immunosuppressed patients, (%) | 1 (17) | 58 (98.3) | 0.021 | Hydroxychloroquine treatment, (%) | 4 (66) | 75 (87) | 0.19 | Steroid dose, mg, mean ± SD | | | 0.11 | Steroid cumulative dose, mg, mean ± SD | | | 0.001 | Cumulative steroids/disease duration, mg/year, mean ± SD | | | 0.021 | Mycophenolate dose, mg, mean ± SD | 0 | | 0.001 | Mycophenolate cumulative dose, mg, mean ± SD | 0 | | 0.001 | Cumulative mycophenolate/disease duration, mg/year, mean ± SD | 0 | | 0.001 | Methotrexate dose, mg, mean ± SD | 0 | | 0.001 | Methotrexate cumulative dose, mg, mean ± SD | 0 | | 0.001 | Cumulative methotrexate/disease duration, mg/year, mean ± SD | 0 | | 0.001 |
|
|